AstraZeneca Pharma India Limited · NSE: ASTRAZEN · BSE: 506820

AstraZeneca Pharma India

Quarterly results as filed with BSE. Latest: Q1 FY27 (Apr–Jun 2026), filed 11 Aug 2026.

Q1 FY27 · Standalone

Revenue
682.79₹ Cr
+29.7% vs year ago
Net profit
37.93₹ Cr
−32.1% vs year ago
EPS, basic
15.17₹
−32.1% vs year ago
Net margin
5.6%
−5.1 pts vs year ago
Revenue₹ crore · standalone · last 12 quarters
Q2 FY24: ₹311.07 CrQ3 FY24: ₹305.79 CrQ4 FY24: ₹383.20 CrQ1 FY25: ₹387.52 CrQ2 FY25: ₹408.00 CrQ3 FY25: ₹440.29 CrQ4 FY25: ₹480.48 CrQ1 FY26: ₹526.31 CrQ2 FY26: ₹559.09 CrQ3 FY26: ₹611.57 CrQ4 FY26: ₹578.61 CrQ1 FY27: ₹682.79 CrQ3 ’24Q1 ’25Q3 ’25Q1 ’26Q3 ’26Q1 ’27
Net profit₹ crore · standalone · last 12 quarters
Q2 FY24: ₹52.37 CrQ3 FY24: ₹15.80 CrQ4 FY24: ₹39.48 CrQ1 FY25: ₹(11.79) CrQ2 FY25: ₹38.43 CrQ3 FY25: ₹30.85 CrQ4 FY25: ₹58.25 CrQ1 FY26: ₹55.83 CrQ2 FY26: ₹54.22 CrQ3 FY26: ₹32.59 CrQ4 FY26: ₹44.88 CrQ1 FY27: ₹37.93 CrQ3 ’24Q1 ’25Q3 ’25Q1 ’26Q3 ’26Q1 ’27

Quarter by quarter

Standalone · ₹ crore
QuarterRevenueYoYNet profitYoYEPS (₹)Filed
Q1 FY27Apr–Jun 2026682.79+29.7%37.93−32.1%15.1711 Aug 2026
Q4 FY26Jan–Mar 2026578.61+20.4%44.88−23.0%17.9526 May 2026
Q3 FY26Oct–Dec 2025611.57+38.9%32.59+5.6%13.0411 Feb 2026
Q2 FY26Jul–Sep 2025559.09+37.0%54.22+41.1%21.6907 Nov 2025
Q1 FY26Apr–Jun 2025526.31+35.8%55.83Turned profit22.3314 Aug 2025
Q4 FY25Jan–Mar 2025480.48+25.4%58.25+47.6%23.3030 May 2025
Q3 FY25Oct–Dec 2024440.29+44.0%30.85+95.2%12.3411 Feb 2025
Q2 FY25Jul–Sep 2024408.00+31.2%38.43−26.6%15.3713 Nov 2024
Q1 FY25Apr–Jun 2024387.52+31.2%(11.79)Turned loss(4.72)09 Aug 2024
Q4 FY24Jan–Mar 2024383.20+34.6%39.48+128.6%15.7928 May 2024
Q3 FY24Oct–Dec 2023305.79+22.4%15.80−46.1%6.3209 Feb 2024
Q2 FY24Jul–Sep 2023311.07+31.7%52.37+60.8%20.9513 Nov 2023
Q1 FY24Apr–Jun 2023295.47+27.2%53.86+167.3%21.5414 Aug 2023
Q4 FY23Jan–Mar 2023284.70+22.7%17.27−38.3%6.9130 May 2023
Q3 FY23Oct–Dec 2022249.81+24.6%29.30+156.6%11.7211 Feb 2023
Q2 FY23Jul–Sep 2022236.13+19.4%32.56+172.6%13.0312 Nov 2022
Q1 FY23Apr–Jun 2022232.33+32.5%20.15+96.7%8.0609 Aug 2022
Q4 FY22Jan–Mar 2022231.96+10.3%27.98+2.6%11.1927 May 2022
Q3 FY22Oct–Dec 2021200.53+0.1%11.42−45.8%4.5709 Feb 2022
Q2 FY22Jul–Sep 2021197.71−5.6%11.95−54.6%4.7810 Nov 2021
Q1 FY22Apr–Jun 2021175.40−90.9%10.24−94.5%4.1010 Aug 2021
Q4 FY21Jan–Mar 2021210.26+7.9%27.28+184.8%10.9126 May 2021
Q3 FY21Oct–Dec 2020200.25−10.5%21.05−21.2%8.4209 Feb 2021
Q2 FY21Jul–Sep 2020209.48+0.5%26.34+82.7%10.5406 Nov 2020
Q1 FY21Apr–Jun 20201,935.78+846.3%186.35+766.1%7.4511 Aug 2020
Q4 FY20Jan–Mar 2020194.90+2.4%9.58−2.5%3.8319 May 2020
Q3 FY20Oct–Dec 2019223.86+4.0%26.70−8.2%10.6804 Feb 2020
Q2 FY20Jul–Sep 2019208.48+29.2%14.42+57.9%5.7712 Nov 2019
Q1 FY20Apr–Jun 2019204.56+26.7%21.52+236.5%8.6108 Aug 2019
Q4 FY19Jan–Mar 2019190.30—9.82—3.9325 May 2019
Q3 FY19Oct–Dec 2018215.19—29.09—11.6407 Feb 2019
Q2 FY19Jul–Sep 2018161.36—9.13—3.6523 Nov 2018
Q1 FY19Apr–Jun 2018161.44—6.39—2.5620 Aug 2018

33 filings on record for this company.